Annexin Pharmaceuticals AB (publ) (ANNX)

Market Closed

10 Aug, 15:25

XSTO

12. 25

-0.4

-3.1621%

- Market Cap

- P/E Ratio

- Div Yield

4,331 Volume

- Eps

kr 12.65

Previous Close

Add Transaction

Day Range

12.25 12.65

Year Range

11.65 39

Want to track ANNX and more in your Portfolio? 🎯

Get Started For Free

Summary

ANNX closed today lower at kr12.25, a decrease of -3.1621% from yesterday's close, completing a monthly decrease of -18.3333% or -kr2.75. Over the past 12 months, ANNX stock lost -33.7838%.

ANNX is not paying dividends to its shareholders.

The last earnings report, released on May 24, 2024, missed the consensus estimates by -0.0359%. On average, the company has fell short of earnings expectations by -0.012%, based on the last three reports.

Annexin Pharmaceuticals AB (publ) has completed 1 stock splits, with the recent split occurring on May 28, 2025.

The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

ANNX Chart

Annexin Pharmaceuticals AB (publ) (ANNX) FAQ

What is the stock price today?

The current price is kr12.25.

On which exchange is it traded?

Annexin Pharmaceuticals AB (publ) is listed on XSTO.

What is its stock symbol?

The ticker symbol is ANNX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Annexin Pharmaceuticals AB (publ) ever had a stock split?

Annexin Pharmaceuticals AB (publ) had 1 splits and the recent split was on May 28, 2025.

Annexin Pharmaceuticals AB (publ) Profile

Biotechnology Industry	Healthcare Sector	- CEO	XSTO Exchange	SE0009664154 ISIN
Sweden Country	4 Employees	- Last Dividend	28 May 2025 Last Split	- IPO Date

Overview

Annexin Pharmaceuticals AB (publ) is a Swedish biotechnology firm that specializes in developing innovative drug candidates aimed at treating a range of cardiovascular diseases. Established in 2014 and headquartered in Stockholm, the company focuses on harnessing the potential of human recombinant proteins to improve vascular health. Its flagship product, ANXV, is designed to protect and repair blood vessels while addressing inflammation associated with various cardiovascular conditions.

Products and Services

ANXV
ANXV is a human recombinant protein that plays a crucial role in vascular biology. This product is aimed at safeguarding the integrity of blood vessel structures while also mitigating inflammatory responses that can lead to further cardiovascular issues. Its development is based on scientific principles that explore the importance of Annexin A5 in preventing damage to blood vessels.
Annexin A5
Annexin A5 serves as a therapeutic offering intended to protect and repair damaged blood vessels. This product leverages the anti-inflammatory properties of the Annexin A5 protein to effectively counteract the inflammatory processes that can exacerbate cardiovascular conditions. Through the application of this protein, Annexin Pharmaceuticals aims to restore vascular functionality and promote healing within the cardiovascular system.

Contact Information

Address: Kammakargatan 48

Phone: -

Website: https://www.annexinpharma.com/sv

Blog Affiliate Program About Terms Privacy Help Contact Us